Abstract
Tumor necrosis factor (TNF)–α inhibitors are a subtype of disease-modifying antirheumatic drugs that have revolutionized the treatment of rheumatologic and gastrointestinal disorders. TNF-α is a cytokine with a complex role in immune system regulation and maintenance of self-tolerance. Despite their clinical benefit in rheumatologic conditions, TNF-α inhibitors have been implicated in the development of CNS and peripheral nervous system disorders.1,2 We describe an asymptomatic patient with radiologic and CSF analysis suggestive of CNS demyelination in the setting of TNF-α therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
